News | February 24, 2023
Sanofi India posts Q4 CY22 PAT at Rs. 130.9 Cr
The company has reported total income of Rs. 691.9 crores during the quarter ended December 31, 2022
The company has reported total income of Rs. 691.9 crores during the quarter ended December 31, 2022
Clinical studies are expected to start in Q2 2023.
Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months
More than 5 lakh patients availed the benefit of queue-less OPD registration using this service
The marketing authorisations for three generic drugs signifying advances in cancer treatment will considerably benefit thousands of patients by improving access, ensuring affordability
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial
Ayurveda is one of the most advanced sciences of its times
This artificial RNA ligase has higher thermostability than natural RNA ligase
First release of Rs.166 crores incentives under PLI scheme for pharmaceuticals
In a bid to better leverage its clinical expertise and drive quality reporting across its centres, Thyrocare has added SigTuple’s AI100 to automate the microscopic review in its laboratories
Subscribe To Our Newsletter & Stay Updated
